Invivyd Revenue

In the year 2025, Invivyd had annual revenue of $53.43M with 110.47% growth. Invivyd had revenue of $17.21M in the quarter ending December 31, 2025, with 24.51% growth.

Revenue (ttm)

$53.43M

Revenue Growth

+110.47%

P/S Ratio

9.94

Revenue / Employee

$534,260

Employees

100

Market Cap

534.10M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	53.43M	28.04M	110.47%
Dec 31, 2024	25.38M	-	-
Dec 31, 2023	-	-	-
Dec 31, 2022	-	-	-
Dec 31, 2021	-	-	-
Dec 31, 2020	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
CorMedix	311.71M
Zevra Therapeutics	84.39M
ADC Therapeutics	75.21M
Prothena Corporation	9.68M
Allogene Therapeutics	22.00K

Revenue Rankings

IVVD News

4 days ago - Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript - Seeking Alpha
4 days ago - Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates - GlobeNewsWire
4 days ago - Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer - GlobeNewsWire
7 days ago - Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 - GlobeNewsWire
7 days ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
13 days ago - New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies - GlobeNewsWire
4 weeks ago - Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration - GlobeNewsWire
6 weeks ago - Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 - GlobeNewsWire

More News